Cannabics Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 06/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume185,636 shs
Average Volume405,800 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CNBX News and Ratings via Email

Sign-up to receive the latest news and ratings for Cannabics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Cannabics Pharmaceuticals logo

About Cannabics Pharmaceuticals

Cannabics Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The company focuses on developing and marketing bioinformatic delivery systems for cannabinoids, personalized medicine therapies, and procedures based on cannabis originated compounds and bioinformatics tools. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, a drug sensitivity test for cannabinoid-based cancer therapies. The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. was founded in 2004 and is based in Bethesda, Maryland. Cannabics Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.42 out of 5 stars

Medical Sector

1789th out of 2,100 stocks

Biotechnology Industry

64th out of 88 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cannabics Pharmaceuticals (OTCMKTS:CNBX) Frequently Asked Questions

What stocks does MarketBeat like better than Cannabics Pharmaceuticals?

Wall Street analysts have given Cannabics Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cannabics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cannabics Pharmaceuticals?

Cannabics Pharmaceuticals saw a drop in short interest in the month of May. As of May 14th, there was short interest totaling 212,300 shares, a drop of 49.4% from the April 29th total of 419,400 shares. Based on an average daily volume of 371,900 shares, the short-interest ratio is currently 0.6 days.
View Cannabics Pharmaceuticals' Short Interest

How has Cannabics Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Cannabics Pharmaceuticals' stock was trading at $0.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CNBX stock has decreased by 36.7% and is now trading at $0.19.
View which stocks have been most impacted by COVID-19

Who are Cannabics Pharmaceuticals' key executives?

Cannabics Pharmaceuticals' management team includes the following people:
  • Mr. Eyal Barad, Co-Founder, CEO & Director (Age 56, Pay $241.12k)
  • Mr. Gabriel Yariv, Pres, COO & Director (Age 44, Pay $151k)
  • Dr. Eyal Ballan Ph.D., Co-Founder & CTO (Age 46, Pay $231.35k)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 51, Pay $75k)
  • Noam Permont, VP of PR & Investor Relations
  • Mr. David E. Price, Corp. Sec. & Corp. Counsel (Age 56)
  • Mr. Yasha Borstein, Chief Data Officer (Age 58)
  • Dr. Yaakov Waksman, Head of Cannabidiol Research (Age 69)
  • Dr. Gil Feiler, Head of Advisory Board & Bus. Devel. Advisor (Age 61)
  • Dr. Sigalit Ariely-Portnoy, Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board (Age 57)

Who are some of Cannabics Pharmaceuticals' key competitors?

What other stocks do shareholders of Cannabics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cannabics Pharmaceuticals investors own include Gran Tierra Energy (GTE), OrganiGram (OGI), KushCo (KSHB), Pennsylvania Real Estate Investment Trust (PEI), Medical Marijuana (MJNA), Auxly Cannabis Group (CBWTF), American Cannabis (AMMJ), GreenGro Technologies (GRNH), MassRoots (MSRT) and Surna (SRNA).

What is Cannabics Pharmaceuticals' stock symbol?

Cannabics Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CNBX."

How do I buy shares of Cannabics Pharmaceuticals?

Shares of CNBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cannabics Pharmaceuticals' stock price today?

One share of CNBX stock can currently be purchased for approximately $0.19.

How many employees does Cannabics Pharmaceuticals have?

Cannabics Pharmaceuticals employs 9 workers across the globe.

What is Cannabics Pharmaceuticals' official website?

The official website for Cannabics Pharmaceuticals is www.cannabics.com.

Where are Cannabics Pharmaceuticals' headquarters?

Cannabics Pharmaceuticals is headquartered at #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States.

How can I contact Cannabics Pharmaceuticals?

Cannabics Pharmaceuticals' mailing address is #3 Bethesda Metro Center, Suite 700, BETHESDA, MD 20814, United States. The company can be reached via phone at +1-877-4242429.

This page was last updated on 6/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.